MedPath

UNIVERSITY OF CINCINNATI

🇺🇸United States
Ownership
-
Established
1819-01-01
Employees
5.9K
Market Cap
-
Website
https://www.uc.edu/

Sympathetic Nervous System Modulation in Hypertension

Phase 4
Terminated
Conditions
Hypertension
Interventions
First Posted Date
2007-06-26
Last Posted Date
2018-02-07
Lead Sponsor
University of Cincinnati
Target Recruit Count
24
Registration Number
NCT00491387

Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease

Phase 4
Terminated
Conditions
Parkinson Disease
Interventions
Biological: Botulinum Toxin Type A
Biological: Placebo
First Posted Date
2007-05-24
Last Posted Date
2009-02-16
Lead Sponsor
University of Cincinnati
Target Recruit Count
8
Registration Number
NCT00477802
Locations
🇺🇸

University Neurology - Movement Disorders Clinic, Cincinnati, Ohio, United States

A Nutrition Intervention to Lower Blood Pressure in Adolescents

Not Applicable
Completed
Conditions
Hypertension
Interventions
Other: Routine nutrition care
Behavioral: diet high in fruits, vegetables, and dairy
First Posted Date
2007-02-05
Last Posted Date
2023-10-02
Lead Sponsor
University of Cincinnati
Target Recruit Count
54
Registration Number
NCT00431288
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)

Phase 2
Completed
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
First Posted Date
2006-12-22
Last Posted Date
2009-05-21
Lead Sponsor
University of Cincinnati
Target Recruit Count
30
Registration Number
NCT00414921
Locations
🇺🇸

Western Psychiatric Institute and Clinic, ADD Program, 3811 Ohara Street, Pittsburgh, Pennsylvania, United States

🇺🇸

University of Rochester Medical Center, Department of Neurology, 919 Westfall Road, Building C, Rochester, New York, United States

🇺🇸

University of Cincinnati, Department of Psychiatry, 231 Albert Sabin Way, M: 0559, Cincinnati, Ohio, United States

Efficacy and Safety of Sirolimus in LAM

Phase 3
Completed
Conditions
Lymphangioleiomyomatosis
Interventions
Drug: Placebo
First Posted Date
2006-12-21
Last Posted Date
2023-11-02
Lead Sponsor
University of Cincinnati
Target Recruit Count
89
Registration Number
NCT00414648
Locations
🇯🇵

National Kinki-Chou Hospital, Sakai, Osaka, Japan

🇯🇵

Niigata University Medical and Dental Hospital, Niigata, Japan

🇺🇸

University of Texas Health Center at Tyler, Tyler, Texas, United States

and more 10 locations

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

Phase 4
Completed
Conditions
Sarcoidosis
Pulmonary Arterial Hypertension
Interventions
First Posted Date
2006-11-27
Last Posted Date
2013-04-12
Lead Sponsor
University of Cincinnati
Target Recruit Count
20
Registration Number
NCT00403650
Locations
🇺🇸

University of Cincinnati, Cincinnati, Ohio, United States

Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine

Phase 4
Completed
Conditions
Bipolar Disorder
Weight Gain
Interventions
Drug: Placebo
First Posted Date
2006-10-31
Last Posted Date
2025-04-09
Lead Sponsor
University of Cincinnati
Target Recruit Count
31
Registration Number
NCT00394095
Locations
🇺🇸

University of Cincinnati Medical Center, Cincinnati, Ohio, United States

Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania

Phase 4
Completed
Conditions
Cannabis-Related Disorder
Bipolar Disorder
Interventions
First Posted Date
2006-10-31
Last Posted Date
2017-09-26
Lead Sponsor
University of Cincinnati
Target Recruit Count
75
Registration Number
NCT00393978
Locations
🇺🇸

University of Cincinnati Medical Center, Cincinnati, Ohio, United States

Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients

Phase 4
Withdrawn
Conditions
Dementia
Behavioral Symptoms
Alzheimer's Disease
Interventions
Drug: Divalproex ER
First Posted Date
2006-09-13
Last Posted Date
2015-05-27
Lead Sponsor
University of Cincinnati
Registration Number
NCT00375557
Locations
🇺🇸

Cincinnati VA Hospital, Cincinnati, Ohio, United States

Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome

Phase 2
Completed
Conditions
Fatigue Syndrome, Chronic
Interventions
Drug: Placebo
First Posted Date
2006-09-13
Last Posted Date
2015-08-21
Lead Sponsor
University of Cincinnati
Target Recruit Count
60
Registration Number
NCT00375973
Locations
🇺🇸

Women's Health Research Program, Cincinnati, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath